FDA issues CRL for aflibercept 8 mg extended dosing for all indications
The CRL issued by the FDA to Regeneron for extended EYLEA HD dosing to 24 weeks cited no safety or efficacy concerns.
Food Insecurity and the Dangers of Infant Formula Dilution
FDA approves dupilumab for chronic spontaneous urticaria in ages 12 and up
The sBLA for dupilumab (Dupixent) was supported by data from the phase 3 LIBERTY-CUPID clinical program in patients with uncontrolled CSU.
Demystifying Infant Formula
ACIP votes in favor of recently FDA approved vaccines for meningococcal disease, chikungunya
Recommendations from the ACIP are forwarded to the director of the CDC, and if adopted, become official CDC policy.
Full case: 2-month-old with scalp swelling
